摘要
目的探讨阿奇霉素联合辛伐他汀治疗慢性阻塞性肺疾病（COPD）合并肺动脉高压的治疗效果及应用价值。方法选择2013年8-10月在航天中心医院进行治疗的COPD合并肺动脉高压患者54例,按照随机数字表法分为观察组和对照组,各27例。对照组进行常规治疗,给予甲硝唑15 mg/kg,6-8 h一次,静脉滴注;观察组在对照组基础上联合阿奇霉素（每次150 mg,每日2次,口服）、辛伐他汀（每次10 mg,每日1次,口服）治疗,两组患者均连续用药20 d。记录并比较两组患者治疗前后血气指标、第一秒用力呼气量（FEV1）和6 min步行距离、呼吸困难分级及不良反应发生情况。结果治疗后观察组血气分析指标动脉血氧分压和动脉血二氧化碳分压分别为（11.64±0.41）kPa、（5.19±0.21）kPa,对照组为（10.88±0.63）kPa、（6.01±0.30）kPa,观察组改善幅度优于对照组（P〈0.01）。治疗后观察组FEV1、6 min步行距离和呼吸困难分级情况分别为（0.98±0.21）L、（131±10）m、（1.2±0.5）级,均优于对照组[（0.72±0.11）L、（101±15）m、（2.9±1.0）级],差异有统计学意义（P〈0.01）。结论采用阿奇霉素联合辛伐他汀治疗COPD合并肺动脉高压的疗效可靠,能改善患者通气功能障碍,增加活动耐力。
Objective To study the therapeutic effect and application value of azithromycin with simvastatin therapy treating chronic obstructive pulmonary disease（ COPD） complicating pulmonary hypertension.Methods Total of 54 patients with COPD complicating pulmonary hypertension admitted to the Aerospace Center Hospital from August to October 2013 were included in the study,and divided into observation group and control group according to random number table method,each group of 27 cases. Patients in the control group were given conventional treatment,metronidazole 15 mg / kg,one time per 6-8 h,intravenous drip.Patients in the observation group were added treatment of azithromycin 150 mg at a time,2 times a day,oral,simvastatin 10 mg at a time,1 time a day,oral,on the basis of therapy in the control group. The medication was administered for 20 d in both groups. The blood gas indexes,forced expiratory volume in one second（ FEV1） and the 6 min walking distance,the dyspnea grade and the adverse reactions of the two groups were recorded and compared. Results After treatment,Pa O2 and Pa CO2 of the observation group were（ 11. 64 ±0. 41） kPa and（ 5. 19 ± 0. 21） kPa,of the control group were（ 10. 88 ± 0. 63） kPa and（ 6. 01 ± 0. 30）kPa,Pa O2 and Pa CO2 in the observation group improved better than those of the control group（ P〈0. 01）.FEV1,6 minutes walking distance and dyspnea of the observation group were better than the control group[（ 0. 98 ± 0. 21） L,（ 131 ± 10） m,（ 1. 2 ± 0. 5）;（ 0. 72 ± 0. 11） L,（ 101 ± 15） m,（ 2. 9 ± 1. 0） ],the differences were statistically significant（ P〈0. 01）. Conclusion Azithromycin combined with simvastatin therapy of COPD complicated with pulmonary hypertension has reliable curative effect,which can improve ventilation dysfunction and increase activity endurance.
出处
《医学综述》
2016年第1期170-172,共3页
Medical Recapitulate
关键词
慢性阻塞性肺疾病
阿奇霉素
辛伐他汀
Chronic obstructive pulmonary disease
Azithromycin
Simvastatin
